Pillar Biosciences

18 articles about Pillar Biosciences

• Pillar Biosciences and KeyGene Enter into Licensing Agreement

  4/13/2023

  Pillar Biosciences, Inc. today announced a non-exclusive licensing agreement with Keygene N.V. related to their patent family entitled Combinatorial sequence barcodes for high throughput screening for use in Pillar Biosciences products, kits or services used for research or clinical testing.

• Pillar Biosciences Receives College of American Pathologists (CAP) Accreditation

  2/7/2023

  Pillar Biosciences, Inc. today announced their receipt of the College of American Pathologists (CAP) Accreditation for its CLIA certified reference lab.

• Pillar Biosciences to Participate in the 2022 Wells Fargo Healthcare Conference

  8/31/2022

  Pillar Biosciences, today announced that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer, will participate in investor meetings at the 2022 Wells Fargo Healthcare Conference at the Encore Boston Harbor in Everett, MA on September 7-9, 2022.

• Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoRevealTM Dx Colon Cancer Assay

  8/22/2022

  Pillar Biosciences Receives China National Medical Products Administration (NMPA) Approval for oncoReveal TM Dx Colon Cancer Assay.

• Pillar Biosciences to Participate in the 2022 UBS Genomics 2.0 and MedTech Innovations Summit

  8/5/2022

  Pillar Biosciences today announced that Randy Pritchard, Chief Executive Officer, will participate in the “Liquid Biopsy in Clinical Practice” panel discussion at the 2022 UBS Genomics 2.0 and MedTech Innovation Sjummit.

• Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx

  7/19/2022

  Pillar Biosciences today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Premarket Approval (PMA) supplement application for its Pan-cancer oncoReveal™ CDx.

• 

  BioSpace Movers & Shakers: Third Harmonic, Inozyme, Athira, Aurion and More

  6/10/2022

  Third Harmonic Bio, Akili Interactive, the Rare Disease Company Coalition, Inozyme, Athira, Cytovia and many more made major leadership decisions this week.

• Pillar Biosciences Strengthens Leadership Team with Appointment of Vincent Ricci as Chief Financial Officer

  6/8/2022

  Pillar Biosciences , the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation and overall testing costs, today announced the appointment of Vincent Ricci as Chief Financial Officer.

• Pillar Biosciences Announces Online Publication of Data in the Journal of Clinical Oncology

  5/31/2022

  Pillar Biosciences , the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) tests to localize testing and reduce time to treatment initiation.

• Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of Its oncoReveal™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants

  4/11/2022

  Pillar Biosciences Presents New Clinical Validation Data Confirming the Accuracy of Its oncoReveal ™ Dx Lung & Colon Cancer Assay in Detecting Clinically Relevant Variants.

• Pillar Biosciences Expands Leadership Team with Appointment of Daniel Harma as Chief Commercial Officer and Christa Adkins as General Counsel

  3/8/2022

  Pillar Biosciences today announced the appointment of Daniel Harma, M.B.A., as Chief Commercial Officer and Christa Adkins, J.D., as General Counsel.

• Pillar Biosciences to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

  2/10/2022

  Pillar Biosciences, an innovative, next-generation sequencing (NGS) solutions, in-vitro diagnostics (IVD) company, today announced that Randy Pritchard, Chief Executive Officer, will present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 16, 2022, at 12:30pm Eastern Time.

• Pillar Biosciences Receives CLIA Certification for its Next-Generation Sequencing Clinical Laboratory

  1/6/2022

  Pillar Biosciences today announced that its NGS laboratory, located in Natick, Massachusetts, has passed the onsite inspection and received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS).

• Pillar Biosciences to Collaborate with Labcorp on Precision Genomic Cancer Testing Using Next-Generation Sequencing

  10/14/2021

  Pillar Biosciences today announced that it has entered into an agreement with Labcorp to provide genomic testing for people with cancer.

• Pillar Biosciences Announces Appointment of Randy Pritchard as Chief Executive Officer

  9/1/2021

  Pillar Biosciences today announced the appointment of Randy Pritchard as Chief Executive Officer.

•  Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal™ Dx Lung and Colon Cancer Assay

  8/5/2021

    Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal ™ Dx Lung and Colon Cancer Assay

• PierianDx and Pillar Biosciences Announce Partnership to Support Precision Cancer Care

  10/14/2020

  PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx cli

• Pillar Biosciences Announces Issuance of China and U.S. Patents Covering SLIMamp Technology

  12/11/2017

  The SIPO of the People's Republic of China issued patent ZL201680001111.1 with a duration of 20 years.